摘要
选择28例类风湿关节炎(RA)作双盲临床试验,全部完成24wk疗程。金诺芬组18例,3mg,qd×2wk,增至3mg,bid共24wk。在晨僵、握力、关节疼痛数和(或)压痛数、关节肿胀数、血沉和C-反应蛋白指标均比安慰剂组10例改善明显。临床缓解和显效率在金诺芬组占89％,在安慰剂组仅40％。提示金诺芬为一有效、安全和方便的改善RA病情药物。
Twenty-eight patients with rheumatoid arthritis were chosen for double-blind clinical trial. The 18 patients in the auranofin group received 3 mg qd po, for 2 wk, increasing to 3 mg bid for a total of 24 wk. This treatment was superior to 10 patients with placebo as measured by improvement in morning stiffness, grip strength, joint pain and/or tenderness, joint swelling, ESR and C-reactive protein. Clinical remission and marked improvement occurred in 89 % of the patients in auranofin group, and 40% in placebo. The results demonstrate that auranofin is effective and safe for the therapy of rheumatoid arthritis.
出处
《新药与临床》
CSCD
北大核心
1992年第1期54-56,共3页
关键词
类风温关节炎
金诺芬
药物疗法
rheumatoid arthritis/drug therapy
auranofin/therapeutic use
clinical trials
